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Cardiac spheroids as promising in 
vitro models to study the human 
heart microenvironment
Liudmila Polonchuk  1, Mamta Chabria1, Laura Badi1, Jean-Christophe Hoflack1, Gemma 
Figtree2, Michael J. Davies  3 & Carmine Gentile2,4,5
Three-dimensional in vitro cell systems are a promising alternative to animals to study cardiac biology 
and disease. We have generated three-dimensional in vitro models of the human heart (“cardiac 
spheroids”, CSs) by co-culturing human primary or iPSC-derived cardiomyocytes, endothelial cells 
and fibroblasts at ratios approximating those present in vivo. The cellular organisation, extracellular 
matrix and microvascular network mimic human heart tissue. These spheroids have been employed 
to investigate the dose-limiting cardiotoxicity of the common anti-cancer drug doxorubicin. Viability/
cytotoxicity assays indicate dose-dependent cytotoxic effects, which are inhibited by the nitric oxide 
synthase (NOS) inhibitor L-NIO, and genetic inhibition of endothelial NOS, implicating peroxynitrous 
acid as a key damaging agent. These data indicate that CSs mimic important features of human heart 
morphology, biochemistry and pharmacology in vitro, offering a promising alternative to animals and 
standard cell cultures with regard to mechanistic insights and prediction of toxic effects in human heart 
tissue.
Engineering of three-dimensional myocardial tissues presents several advantages for cultures of primary cardio-
myocytes (CMs) to study human heart biology, physiology and pharmacology1–3. In contrast to monolayer cul-
tures, CMs cultured in a three-dimensional environment have prolonged viability and can retain their contractile 
properties. For instance, CMs cultured in a three-dimensional alginate matrix retain their sarcomeric structure 
for up to 14 days in contrast to a few days in a monolayer culture4. Similarly, Chan et al.5 showed that neonatal rat 
CMs retain their contractile properties when cultured in a three-dimensional multi-strip cardiac muscle contain-
ing fibrinogen and Matrigel. Co-cultures of CMs with other cell types, such as endothelial cells (ECs) and cardiac 
fibroblasts (CFs), also improve engraftment and functional features in an in vivo myocardial infarction (MI) 
model compared to sheets of CMs alone6.
As primary cardiomyocyte sources are limited, stem cell-derived CMs have emerged as a promising cell source 
to model the human heart, with obvious advantages for toxicity and drug discovery studies, and regenerative 
therapy7, 8. One of the main limitations of human pluripotent stem cell-derived CMs or cardiac progenitor cells 
is their immature phenotype, with these having contractile and other biological and physiological properties 
that differ from those of human adult CMs9–12. Although Fernandes et al.13 have shown that stem cell-derived 
CMs and cardiac progenitor cells of different sources have similar regenerative properties in an in vivo myocar-
dial infarction model in mice, a deeper understanding of the requirements for optimal engineering of a human 
heart model in vitro is important14. Approaches include use of different cell sources and methods that alter the 
phenotype from immature to adult CMs. Scaffold-based and scaffold-free approaches can be applied to engineer 
the heart12, 15. However, most of the cardiac tissue models contain only CMs and lack the other cell types present 
in the human heart, such as ECs and CFs. Caspi et al.16 have generated vascularized cardiac tissue by seeding 
ESC-derived CMs, ECs and CFs into a scaffold. This approach has considerable advantages as pre-vascularization 
of cardiac tissues has been shown to be crucial in determining therapeutic outcomes17.
In this study we developed a 3D in vitro model of the human heart microenvironment using ECs, CFs 
and adult CMs (the human cardiac spheroid, hCS) in proportions similar to those found in the human heart. 
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A similar approach has been used to develop a 3D co-culture from commercially available iPSC-derived cells 
(iPSC-derived cardiac spheroid, iCS). These models have been used to elucidate the mechanism of cardiotoxicity 
of the widely-used anti-cancer drug, doxorubicin (DOX; also named adriamycin) which can modulate nitric 
oxide (NO) levels.
Constitutive synthesis of NO in the heart has been associated with a cardioprotective role played by this 
molecule in both an autocrine18, 19 and paracrine20 manner (via ECs). While low concentrations of NO have car-
dioprotective effects21, increased levels of NO associated with oxidative stress and peroxynitrous acid generation, 
have been suggested to be responsible for the undesired cardiotoxic effects of anthracyclines, such as DOX22–25 
dramatically limiting their use as chemotherapeutic agents26–29. Among the different proposed mechanisms, reac-
tive oxygen species (ROS) seem essential for mediating anthracycline-induced cardiotoxicity and DNA damage 
following its subcellular accumulation30–35. Recent in vitro and in vivo data suggest an alternative mechanism to 
target DOX/ROS-mediated cardiotoxic effects, which may involve NO synthases (NOS)36–41. This led us to inves-
tigate if, and how, NO mediates DOX-induced cardiotoxic effects in human heart cells, and the dual cardioprotec-
tive and cardiotoxic role of this species, which highlights the importance of cellular crosstalk.
Results
Generation of cardiac spheroids from primary and iPSC-derived cardiac cells. To investigate the 
roles played by the microenvironment in the human heart we have developed a 3D in vitro “cardiac spheroid” 
model of the human heart. Hanging drop cultures of cells normally found within the human heart were prepared 
using human coronary artery endothelial cells (ECs), cardiac fibroblasts derived from iPSCs (iCFs) and either 
human primary adult cardiomyocytes (hCMs) or iPSC-derived cardiomyocytes (iCMs, Fig. 1). hCMs were iso-
lated from frozen heart sections, retaining the biochemical, morphological and physiological features of fresh 
human heart tissue (Fig. S1a–c). Similar human heart sections were used to compare the expression levels of 
markers in spheroids and ex vivo.
These spheroids have been named according to their cell population: human (hCSs) and iPSC-derived cardiac 
spheroids (iCSs). Due to differences in cell size between hCMs and iCMs (approximately 150 μm and 50 μm in 
length, respectively) and the limited viability of hCMs in culture, we employed different cell ratios to mimic the 
in vivo cardiac microenvironment and to support spheroid formation. We increased the number of iCFs and ECs 
to maintain hCMs in culture, with a ratio of 1:3:6 for hCM:EC:iCF, respectively. iCMs were co-cultured in a ratio 
of 2:1:1 for iCM:EC:iCF, respectively. The different cell types and ratios affected the kinetics of CS formation, with 
hCSs forming aggregates within 24 h due to the higher numbers of iCFs, whereas iCSs with less iCFs required 
four days to completely aggregate in hanging drop cultures (Fig. 1). TEM analysis showed that hCSs retain their 
sarcomeric structure in these 3D in vitro cultures (Fig. S2). To elucidate the role of individual cell types, sphe-
roids were also generated containing one or two of the cell types. Hanging drop cultures of hCMs alone did not 
aggregate and eventually died as indicated by the presence of cell debris after 2 weeks in culture, whereas iCMs 
aggregated, but formed loose non-spherical clusters (data not shown). Co-cultured hCMs and ECs formed small 
aggregates but these did not coalesce into a single large spheroid (data not shown). Following spheroid formation, 
iCSs exhibited synchronous contraction in hanging drop cultures (see Videos S1 and S2 “mini beating heart”) 
Figure 1. Generation of cardiac spheroids in hanging drop culture. (a) Representative bright-field images 
of human primary cardiomyocytes (hCM), iPS-derived cardiac fibroblasts (iCF) and human coronary artery 
endothelial cells (ECs) co-cultured in hanging drops for 0, 2, 6, 12 and 24 h. (b) Representative bright-field 
images of hiPS-derived cardiomyocytes (iCM), iCF and ECs in hanging drop co-cultures after 0, 12, 24, 48 and 
96 h. Scale bars: 100 μm. See also Figs S1, S2 and Videos S1 and S2.
www.nature.com/scientificreports/
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demonstrating that these multiple-cell type CSs have structural and functional characteristics representative of 
human heart tissue.
Cardiac fibroblasts and endothelial cells control the three-dimensional behavior of cardiac 
myocytes. The biochemical properties of these cardiac spheroids were investigated by immuno-staining 
using antibodies against markers for CMs (cardiac Troponin T), CFs (vimentin) and ECs (PECAM). Confocal 
analysis showed that both hCSs and iCSs have a significant vascular network (Fig. 2a and c). The inserts in Fig. 2a 
and c show that ECs line the vascular network, with CMs in closely proximity, as observed in human tissue 
sections. iCFs are present both on the surface and throughout the spheroid, in support of the developing vas-
cular network of both hCSs and iCS. Analysis of iCSs showed that vimentin-positive iCFs are adjacent to devel-
oping PECAM-positive microvascular network (Fig. S3a–c). Imaris 3D rendering analysis of iCSs showed that 
iCFs alone define a supporting structure for this network that allows vascularization throughout the spheroid 
(Fig. S3d–f).
The deposition of ECM molecules in both hCSs and iCSs was also examined. Analysis of confocal images of 
ex vivo heart sections, hCSs and iCSs showed similarities to both in vitro models and human heart tissue (Fig. 3), 
with a network of fibronectin, collagen type IV and laminin present in each case. The more regular organisation 
in hCS may be due to the higher numbers of CMs in the iCSs. ECM deposition was distributed within tissues 
according to the sorting of ECs and iCFs (Fig. 2).
Overall, these data demonstrate that both hCSs and iCSs mimic the cellular and molecular composition of 
human heart tissue.
Doxorubicin-mediated toxic effects on hCSs and iCSs. To evaluate if hCSs and iCSs could be used 
as in vitro models to study human heart toxicology, they have been treated with increasing concentrations of a 
known cardiotoxic agent, doxorubicin (DOX). To evaluate its toxic effects on hCSs and iCSs, we have measured 
dead versus live ratios in controls, and hCSs and iCSs treated with 1-40 μM DOX (Fig. 4a). Peak plasma concen-
trations of DOX in patients are in the range 5-10 μM42–45. Statistical analyses showed a similar trend of response 
for hCSs and iCSs (Fig. 4a), with a statistically-significant increase at DOX concentrations within the therapeutic 
range. The concentration-dependent increase in DOX-mediated toxic effects was correlated with the number of 
CMs present in hCMs and iCMS, with almost a two-fold increase at 40 μM in hCSs (containing 1000 hCMs) ver-
sus an 8-fold increase in iCSs (containing 5000 iCMs) at the same concentration. The number of iCMs contained 
within iCSs is six-fold higher compared with the number of hCSs contained within hCSs. Data normalization 
against the number of CMs in the different spheroid types in Fig. 4a demonstrates that the increase in DOX–
induced toxicity was similar between hCSs and iCSs. Hence, although the iCS have a greater representation of 
cardiomyocytes than the hCS, both appear to be similarly vulnerable to DOX-mediated toxicity.
Figure 2. Sorting of cardiomyocytes, endothelial cells and fibroblasts within cardiac spheroids. (a–d) PECAM-
positive ECs (blue) form a microvascular network within hCSs (a,b) and iCSs (c,d) in hanging drop cultures. 
Vimentin-positive iCFs (green) sort out both on the surface and within hCSs (a,b) and iCSs (c,d). Cardiac 
Troponin T-positive iCMs (red) are surrounded by both ECs and iCFs in hCSs (a,b) and iCSs (c,d). Scale bars: 
100 μm in (a,b), 200 μm in (c,d). See also Fig. S3.
www.nature.com/scientificreports/
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Several studies have demonstrated a complex mechanism of DOX action on human heart tissue involving free 
radical formation, calcium dysregulation, mitochondrial dysfunction and topoisomerase II inhibition46. Reactive 
oxygen species (ROS) have been suggested to be responsible for most of the toxic effects in ECs in the human 
heart via eNOS uncoupling and peroxynitrous acid generation, with the latter arising from reaction of nitric 
oxide with superoxide47. To evaluate DOX-mediated intracellular NO synthesis, we measured DAF-FM diacetate 
fluorescence in both DOX-treated hCSs and iCSs (Fig. 4b). Our analyses demonstrated a statistically-significant 
increase in DOX-mediated NO synthesis starting at 10 μM in hCSs and 5 μM in iCSs. These differences probably 
arise from a lower level of NO formation by iCSs and their greater sensitivity to DOX due to the different cell 
ratios. L-NIO, a non-specific eNOS competitive antagonist, significantly alleviated DOX-mediated toxic effects 
in these cultures at concentrations above 10 μM (Fig. 4a). Interestingly, NOS inhibition by L-NIO did not rescue 
DOX toxicity in pure cardiomyocyte spheroids, whereas 2D cardiomyocyte monolayers, which were affected to a 
greater extent by DOX, showed a limited positive effect of L-NIO (Fig. S4).
Confocal analysis of DOX-treated hCSs and iCSs stained with antibodies against active caspase 3 demon-
strated that DOX-mediated apoptosis is inhibited in L-NIO-pre-treated spheroids (Fig. 5). In accordance with the 
data in Fig. 4, the extent of DOX-induced apoptotic effects in hCSs and iCSs appears to reflect the cell ratios used 
to generate the spheroids, and particularly their CM content.
Figure 3. Extracellular matrix (ECM) deposition ex vivo and in vitro. Fibronectin (a), collagen type IV (b) and 
laminin (c) deposition within human heart sections, hCSs and iCSs (green). Nuclei are stained with Hoechst 
stain (blue). Scale bars: 200 μm.
www.nature.com/scientificreports/
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Taken together, these data suggest that DOX-mediated toxicity and apoptosis in hCSs and iCSs is dependent 
on NO signalling.
eNOS-mediated NO synthesis as a molecular target for DOX-induced toxic effects in the 
human heart. Based on the data demonstrating an NO-dependent DOX-induced toxic effect in iCSs, 
we examined the cell types responsible for this effect. To this end, we compared DOX-mediated effects using 
spheroids generated with only two out of the three cell types (iCMs, iCFs and ECs) (Fig. 6a). Statistical analysis 
demonstrated a protective role for ECs in co-cultures with either iCMs or iCFs after DOX treatment, whereas 
iCM-iCF co-cultures without ECs showed a similar response to DOX as observed in iCSs. The toxic action of 
DOX was restored by inhibition of NO synthesis with L-NIO in the iCM-EC, but not in the EC-iCF co-cultures 
further supporting the protective role of ECs and toxic effects of iCFs on iCMs, with CMs being the main target 
of damage.
In order to examine the molecular mechanisms of DOX-mediated toxic effects in iCSs, and the role of eNOS, 
one of the enzymes that constitutively generates NO in the heart, we stably silenced eNOS in either iCMs, or ECs 
or iCFs using NOS3 shRNAs prior to the formation of iCSs. Statistical analyses showed that silencing of eNOS in 
any cell type prevented DOX-mediated effects on iCSs at 10 μM, with the strongest inhibitory effect observed in 
NOS3-silenced iCFs, followed by ECs and then iCMs (Fig. 6b).
Overall these data (summarized in Fig. 7) suggest that iCSs are suitable models to study toxic effects in a com-
plex multicellular microenvironment such as the human heart. Additionally, it opens a new field of study based 
on the novel role played by iCFs in DOX-induced toxicity.
Discussion
In this study, we have established for the first time the microenvironment or niche required to mimic the in vivo 
milieu of the human heart in vitro. This is based on direct analysis of cellular and extracellular features of the 
human heart ex vivo. Our data confirm that the ratio of different cell populations (CMs, CFs and ECs) is critical to 
successful modeling of the behaviour of the human heart. Adult CMs represent ~30% of the total cell population 
in a human heart, with a ratio of ECs and CMs equal to 3:1, even though the mass ratio of these two cell types is 
Figure 4. Inhibition of nitric oxide synthesis prevents DOX-mediated cardiotoxic effects in hCSs and iCSs. (a) 
Statistical analysis (n = 6) of DOX-mediated cardiotoxic effects in hCSs and iCSs evaluated as a ratio between 
dead and live cells after 24 h treatment. 100 μM L-NIO prevents the doxorubicin-mediated effects in both 
hCSs and iCSs treated with 10, 20 and 40 μM doxorubicin. (b) Statistical analysis (n = 6) of DAF-FM-positive 
cells in hCSs and iCSs following 24 h doxorubicin treatment. *Relative to control for all groups; ♯Within the 
same concentration. Data are presented as mean ± SEM. One-way ANOVA followed by Bonferroni’s multiple 
comparisons test. F (df 10, 55)=40.53 for (a) hCS, F (df 10, 143) = 253 for (a) iCS, F (5, 30) = 37.33 (b) hCS and 
F (5, 30)=56.09 for (b) iCS. See also Fig. S4.
www.nature.com/scientificreports/
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0.04–0.05. In contrast, CFs represent ~ 60% of the cell population12, 48–50. To investigate the human heart proper-
ties in vitro we utilized human heart specimens to generate 3D in vitro models.
Generating hCSs from primary CMs of healthy and diseased specimens has great potential for disease mod-
elling. However, based on our findings, primary CMs don’t survive in culture for extended periods without sup-
porting cells. We therefore increased the ratio of CFs and ECs for the generation of hCSs with a final ratio of six 
CFs to three ECs and one CM. However, human heart specimens are not commonly available, which limits their 
use in generating in vitro models for high throughput assays. For this reason, we investigated whether CSs could 
be generated from commercially available iCMs. There are clear limitations associated with the use of iPSC-CMs 
containing iCSs, as these cells retain an embryonic/neonatal phenotype compared to primary cells (e.g. sponta-
neous beating in culture11). We therefore used different cell ratios for iCSs, to better mimic observed ex vivo cell 
populations by co-culturing two iCMs, one EC and one CF, reflecting the differences in cell size and ratios present 
in young versus adult human hearts.
The vascular network observed in hCSs and iCSs reflects the ratio of cells used. Compared to hCSs, the vascu-
lar networks in iCSs followed the path generated by ECs and CFs (Fig. 2), where these cells aggregated in multiple 
areas and from which several ramifications form (Fig. S3). Interestingly, CFs appear to play a supportive role for 
the vascular network formation within iCSs, by providing the required ECM scaffold for ex novo microvascu-
lar network formation from single ECs (Fig. S3). The only other attempt to evaluate the possible advantages of 
co-culturing iCMs with ECs and CFs is from Ravenscroft et al.51 who demonstrated that co-cultured microtis-
sues better replicate the biochemical and physiological properties of the human heart compared to iCMs alone. 
Beside the differences in the kinetics of formation of the cardiac microtissues generated in this previous study 
and our iCSs (two weeks versus four days, respectively), these two models differ in other aspects. Thus, they are 
generated using different culturing conditions (non-adherent plates versus hanging drop cultures), but more 
importantly the cardiac microtissues lack the microvascular network formation observed in our iCSs (Fig. S3). 
This could be explained by the differences in the ratios and total numbers of cells used. Morphological differences 
between these two 3D in vitro models may also affect their behavior. For instance, apoptosis typically occurs in 
the center of any tissue with a radius bigger than 200 μm in the absence of a preformed vasculature12, 52. Our gene 
profiling data demonstrate that iCSs are similar to human LV specimens (data not shown, provided for review in 
Figure 5. Doxorubicin-mediated apoptosis is inhibited by L-NIO. (a) Confocal analysis of hCSs and iCSs 
cultured with and without 20 μM DOX and 100 μM L-NIO and stained with antibodies against active caspase 3 
(shown in red). (b) Statistical analysis (n = 3) of black-versus-white ratios of confocal images of hCSs and iCSs 
cultured and stained as described in panel (a). Data are presented as mean ± SEM. Scale bars: 200 μm. One-way 
ANOVA followed by Bonferroni’s multiple comparisons test. F (df 5, 12) = 1.153.
www.nature.com/scientificreports/
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supplementary information). This would affect the dose response to pharmacological agents acting on the heart. 
In order to evaluate the use of iCSs as a model to predict toxicological effects on the human heart, we treated them 
with DOX, a well-known cardiotoxic agent. DOX-induced oxidative stress and cardiotoxicity has been suggested 
to occur via increased endothelial nitric oxide synthase (eNOS) expression and activity22–25.
Previously reported mechanisms for DOX-mediated cardiotoxic effects detected with a cumulative dose 
of 100-600 mg/m2, include lipid peroxidation, mitochondrial dysfunction and apoptotic pathways, with these 
effects dramatically limiting its use as a chemotherapeutic agents26–29. A severe late-onset dilated cardiomyopa-
thy (more than one year after completion of treatment) is often observed in DOX-treated young patients with a 
dose > 250 mg/m2 24, 53, 54, and in both overweight55 and other adults at a cumulative dose > 450 mg/m2 56. Among 
the proposed mechanisms, reactive oxygen species (ROS) seem to play a mayor role30–35.
At low physiological concentrations NO plays a protective role in the heart where it is constitutively syn-
thesized by eNOS in both CMs and ECs21. It is important to note that human CMs express all NOS isoforms 
(eNOS, iNOS and nNOS), whereas ECs express both eNOS and iNOS, but not nNOS. Few previous reports have 
demonstrated eNOS expression in CFs, possibly due to the culture conditions and cell stage57–61. Interestingly, 
Ravenscroft et al.51 also measured increased levels of eNOS in CFs compared to CMs.
Kaliventhi et al.62 showed that both chemical and genetic inhibition of eNOS in ECs exacerbated DOX-induced 
ROS production, providing evidence for cross-talk between ROS and NO synthesis in ECs. It is therefore possible 
that it is the combination of DOX-induced ROS and NO syntheses that mediates toxic effects via peroxynitrous 
acid generation.
The data obtained here for the 3D spheroids of either iCMs alone, or these cells together with other support-
ing cells, indicate that NO from ECs plays a protective role in CMs from DOX, probably via eNOS uncoupling. 
Similar to our data (Fig. 6), Kalivendhi et al.62 have shown that DOX treatment increases eNOS transcription 
and protein activity in BAECs, and DOX-induced apoptosis can be rescued by antisense eNOS mRNA. Similarly, 
Kalivendhi et al.62, showed that pharmacological inhibition with a competitive antagonist of eNOS increased 
DOX-induced apoptosis, as seen in co-cultured HCAECs/iPSC-CM spheroids. Our data for iCSs confirm the 
protective role played by NO from ECs following DOX treatment, together with its mediation of toxic effects by 
increasing peroxynitrous acid generation and caspase 3 activation (Fig. 7).
Figure 6. DOX toxicity is mediated via NOS in different cell types. (a) Comparison of DOX-mediated toxic 
effects in co-cultures from different cell populations (n = 6): (i) iCS generated from iCM, EC and iCF; (ii) 
iCMs combined with ECs only; (iii) iCMs combined with iCFs only; and iv) ECs combined with iCFs. 100 μM 
L-NIO was used to inhibit NOS activity. Two-way ANOVA followed by Tukey’s multiple comparisons test. F (df 
7, 32) = 17.13. (b) Comparison of DOX-mediated toxicity in iCSs where eNOS was inhibited by using eNOS 
shRNA in specific cell types (n = 6). Scramble shRNA was used as control. *Relative to iCS; ♯within the same cell 
population. Data are presented as mean ± SEM. Two-way ANOVA followed by Tukey’s multiple comparisons 
test. F (df 4, 40) = 5.846.
www.nature.com/scientificreports/
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Our study has identified, for the first time, the toxic role played by cardiac fibroblasts in DOX-induced apopto-
sis of cardiomyocytes via NO. Similar to the effect observed using iCFs in iCSs, DOX has previously been shown 
to induce caspase 3-mediated apoptosis in mouse embryonic fibroblast cultures via ROS production in a more 
potent manner compared to H2O236. Prior to our study, it was not clear whether DOX-induced toxic effects in 
these cells occured upstream of eNOS, or via other isoforms such as iNOS38. Our data support a role for eNOS in 
CFs to mediating DOX-induced toxic effects on CMs, based on our chemical and genetic inhibition of eNOS in 
these cells (Fig. 7). Interestingly, NOS inhibition by L-NIO did not protect against the DOX toxicity in the iCMs 
in 3D cultures, whereas 2D iCMs monolayer cultures, which were more markedly affected by the drug, showed a 
limited positive effect of L-NIO (Fig. S4).
These findings suggest an alternative mechanism to target DOX/ROS-mediated cardiotoxic effects involving 
eNOS37. As DOX is a first choice agent to treat several cancers, this novel mechanism of DOX-mediated cardio-
toxicity via CFs, opens a new field of investigation for inhibiting cardiomyopathies in cancer patients. Our study 
also highlights the advantages of the co-culture approach compared to current cell culture practices, as CSs rep-
resent a more reliable and nuanced model of the behavior of the human heart with regard to cardiotoxic effects, 
and also for the study of basic and translational biology and physiology.
Possible further applications for iCSs include their use as building blocks for 3D bioprinting thanks to their 
pre-formed vascular network and capacity to undergo self-assembly. These properties make them suitable for 
generation of bioengineered models of the human heart of both increased size and complexity, including studies 
on blood flow and mechanical stimuli12, 52.
Methods
Drugs and reagents. Primary antibodies: Mouse monoclonal antihuman CD31/PECAM was purchased 
from BD Pharmingen (San Diego, CA, USA). Mouse monoclonal anti-α-actinin (Sarcomeric) was purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Mouse monoclonal [1C11] anti-human Cardiac Troponin T (Texas 
Red®), mouse monoclonal [A17] to fibronectin, rabbit polyclonal to laminin, rabbit polyclonal to collagen type 
IV, mouse monoclonal [V9] to vimentin (Alexa Fluor® 488) and rabbit polyclonal to active caspase-3 antibodies 
were purchased from Abcam (Cambridge, MA, USA). Secondary donkey anti-rabbit and anti-mouse secondary 
fluorochrome-conjugated antibodies were from Jackson Immunological Research Labs, Inc., West Grove, PA, 
USA. NucBlue® Live ReadyProbes® Reagent (Hoechst 33342) was purchased from Invitrogen (Carlsbad, CA, 
USA). Extracellular matrix: Fibronectin from bovine plasma was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Drugs: L-NIO (N5-(1-iminoethyl)-L-ornithine, dihydrochloride, used at 100 μM) was purchased from 
Cayman Chemical (Ann Arbor, MI, USA). Doxorubicin hydrochloride (used at 1, 5, 10, 20 and 40 μM) was pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
Cells and cardiac spheroid formation. Human primary cardiomyocytes (hCMs) were isolated from 
human heart sections of left ventricular myocardium from healthy unused donor hearts that were first thawed 
from liquid nitrogen to 37 °C and then digested enzymatically. Human specimens were kindly obtained from the 
Figure 7. Cross-talk between different cell types in DOX-induced cardiotoxicity. (a) DOX-induced effects on 
cardiomyocytes occurs via ROS/caspase 3-mediated apoptosis. (b) EC-released NO protects cardiomyocytes 
against DOX-induced toxicity. (c) DOX-induced eNOS up-regulation in endothelial cells produces toxic NO 
species. (d) DOX-induced eNOS up-regulation in cardiac fibroblasts produces the majority of the toxic NO 
species. (e) DOX-induced cardiotoxic effects via ROS production in cardiac fibroblasts. At the molecular level, 
DOX/superoxide-induced apoptosis in cardiomyocytes can be either rescued by endothelial cell-released 
NO, via inhibition of a ROS-mediated toxic effect, or can be exacerbated by increased eNOS expression and 
peroxynitrous acid formation. Cardiac fibroblasts can trigger DOX/NO-toxic effects by overexpressing eNOS 
and increasing peroxynitrous acid generation, or could increase superoxide levels and therefore feedback to 
endothelial cell-mediated peroxynitrous acid and cardiomyocyte apoptosis.
www.nature.com/scientificreports/
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Sydney Heart Bank at the University of Sydney. Human tissue was used in accordance with the ethical guidelines 
of the University of Sydney Human Research Ethics Committee, from which Human Research Ethics Committee 
approval was previously obtained (Project Title: The Sydney Human Heart Tissue Bank (SHB), Project No: 
2012/2814). Signed patient consent was obtained for all samples in this tissue bank. For cardiomyocyte isolation, 
300 μm frozen sections were digested at 37 °C in Krebs buffer (120 mM NaCl, 4.7 mM KCl, 25 mM NaHCO3, 
1.2 mM KH2PO4, 1 mM MgSO4, 1.2 mM CaCl2, 12 mM glucose, 100 μM ascorbic acid, pH = 7.4) containing 1 mg/
ml collagenase B (Roche, Basel, CH), 1 mg/ml collagenase D (Roche, Basel, CH) and 30 mM 2,3-butanedione 
monoxime (BDM) for 20 min under agitation. Sections were then mechanically dissociated using a pipet and 
filtered using a 200 μm mesh to collect single cells and remove undigested tissue. Viability of rod-shaped striated 
cardiomyocytes was evaluated using Trypan Blue staining.
Cor.4U induced pluripotent stem cell-derived cardiomyocytes (iCMs) and fibroblasts (iCFs) were obtained 
from Axiogenesis (Cologne, Germany). Human coronary artery endothelial cells (HCAECs) were purchased 
from Cell Applications, Inc (San Diego, CA, USA). Cells were plated and cultured according to supplier’s instruc-
tions. iCMs and iCFs were cultured in Cor.4U Culture Medium (Axiogenesis), whereas HCAECs were cultured 
in Human MesoEndo Cell Growth Medium (Cell Applications, Inc).
Human cardiac spheroids (hCSs) were generated by co-culturing 1000 hCMs (immediately after their isola-
tion) with 3000 ECs and 6000 iCFs in 40 μl hanging drop cultures, whereas induced pluripotent cardiac spheroids 
(iCSs) were generated by combining 6000 iCMs together with 3000 ECs and 3000 iCFs in 40 μl hanging drop 
cultures using the Perfecta 3D® 96 well Hanging Drop Plates (3D Biomatrix, Ann Arbor, MI, USA). Single or 
two cell type spheroids were generated in hanging drop cultures using: i) 6000 iCMs alone; ii) 6000 iCMs plus 
3000 ECs; iii) 6000 iCMs plus 3000 iCFs; iv) 3000 ECs plus 3000 iCFs. Drug treatment was conducted following 1 
day (hCSs) or 4 days (iCSs) in hanging drop cultures in the same well for 24 h. To allow tissue penetration, L-NIO 
was added 1 h prior to DOX.
Tissue and spheroid immunolabeling and confocal imaging. Spheroids were fixed in 4% paraformal-
dehyde for 60 min and permeabilized in phosphate buffered saline/0.01% sodium azide (PBSA) containing 0.02% 
Triton-X-100 (60 min). Tissue slices and spheroids were then blocked with a 3% bovine serum albumin (BSA)/
PBSA solution, and then incubated with appropriate primary (15 μg/ml) and secondary (10 μg/ml) antibodies 
overnight at 4 °C. Tissues and spheroids were incubated with antibodies against cTNT, CD31 and vimentin, to 
stain hCMs/iCMs, ECs and iCFs, respectively. DNA Hoechst stain for nuclei labelling (Invitrogen, Carlsbad, CA, 
USA) was added together with the secondary antibody. Specimens were mounted using Vectashield® Mounting 
Medium (Vector Laboratories, Burlingame, CA, USA). Fluorescent imaging used a Zeiss LSM 510 Meta Spectral 
Confocal Microscope (Carl Zeiss AG, Oberkochen, Germany). Optical sectioning along the Z axis was performed 
and the images collapsed into a single focal plane using the manufacturer’s software. Images were processed 
using NIH Image 1.47 v software (National Institutes of Health, Bethesda, MD, USA) and Adobe Photoshop 
CS5 (Adobe Systems, Inc., San Jose, CA, USA). For 3D reconstructions, images were processed by Imaris V 7.6 
(Bitplane, Concord, MA, USA).
Toxicity assay. Monolayer cultures of iCMs were plated and CSs were transferred in 96-well clear bottom 
black polystyrene microplates (Corning®, New York, NY, USA) 24 hours prior to their treatment with DOX and/
or L-NIO. Live/Dead® Viability/Cytotoxicity Kit for mammalian cells (Invitrogen, Carlsbad, CA, USA) was used 
according to manufacturer’s instructions to evaluate toxicity, calculated as a ratio between dead versus live cells, 
measured in each well at 645 nm (for ethidium homodimer) and 530 nm (calcein-AM), respectively. Ratios were 
normalized against the number of cells present within the spheroid and against the control culture (untreated 
spheroids in case of hCSs and iCSs, iCSs at the different DOX concentrations in case of comparing studies). 
GraphPad Prism™ (La Jolla, CA) was used for data analysis and statistics.
Apoptotic assay. Fixed spheroids were exposed sequentially to the primary active caspase 3 antibody (15 μg/
ml) and secondary (10 μg/ml) antibodies (both overnight, 4 °C), and then stained with Hoechst stain. They were 
imaged using a Zeiss LSM 510 Meta Spectral Confocal Microscope (Carl Zeiss AG, Oberkochen, Germany) and 
active caspase 3-positive area over total area were measured using a black-to-white ratio by using NIH ImageJ 
1.47v software (National Institutes of Health, Bethesda, MD, USA) and Adobe Photoshop CS6 (Adobe Systems, 
Inc., San Jose, CA, USA). Active caspase 3 measurements were normalized against the number of cells and against 
the control (untreated spheroids) and then analyzed using GraphPad Prism™ (La Jolla, CA).
Intracellular NO synthesis. Intracellular NO was detected by using DAF-FM diacetate (Invitrogen, 
Carlsbad, CA, USA) as previously described63. Briefly, hCSs and iCSs were treated in presence of DOX with or 
without L-NIO for 24 h in hanging drop plates. Spheroids were then transferred in clear bottom black 96 well 
plates by centrifugation. Spheroids were rinsed twice with PBS and 1 μM DAF-FM diacetate solution was prepared 
freshly in PBS. After 30 min, DAF-FM diacetate solution was removed, spheroids were rinsed twice with PBS and 
fresh PBS was added for 30 min. For measurements of NO synthesis, the microplate was placed in the FlexStation® 
3 Multimode Plate Reader (Molecular Devices, Sunnyvale, CA, USA) and measurements were recorded at 515 nm. 
NO synthesis was calculated by normalizing measurements against total number of cells and then against control 
(media only without DOX and/or L-NIO), and analysed using GraphPad Prism™ (La Jolla, CA).
eNOS Silencing. iCMs, ECs and iCFs were cultured separately in T75 flasks and transfected with either 
NOS3 or scrambled shRNA lentiviral particles (SantaCruz Biotechnology, Dallas, TX, USA). Both shRNA lenti-
viral particles were diluted in media containing Polybrene (SantaCruz Biotechnology, Dallas, TX, USA) to give 
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a final concentration of 1% (v/v) of lentiviral particles. Cells were incubated with transfection solution at 37 °C, 
under 5% CO2 for 24 h prior to their use for iCS generation.
Statistical analysis. Experimental data are expressed as the mean ± SEM from at least three independent 
experiments. ANOVA followed by Bonferroni post hoc test was performed using GraphPad Prism™ (La Jolla, CA).
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